Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection

(2014) S. Saab et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation

(2014) D Hartwell et al.   HEALTH TECHNOLOGY ASSESSMENT

Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

(2014) Salvatore Petta et al.   HEPATOLOGY

Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response

(2014) Kian Bichoupan et al.   HEPATOLOGY

New Expensive Treatments for Hepatitis C Infection

(2014) Troyen Brennan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

World Gastroenterology Organisation Global Guidelines

(2014) Muhammed Umar et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141)

(2014) Sylvie Deuffic-Burban et al.   JOURNAL OF HEPATOLOGY

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

(2014) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

(2014) Klazien Matter-Walstra et al.   PHARMACOECONOMICS

Hepatitis C can be cured globally, but at what cost?

(2014) A. Hill et al.   SCIENCE

Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data

(2013) Hansoo Kim et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics

(2013) Anuoluwapo Osinusi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

(2013)   JOURNAL OF HEPATOLOGY

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

(2013) Eric Lawitz et al.   LANCET INFECTIOUS DISEASES

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

(2013) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

(2013) Edward J. Gane et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

(2013) Eric Lawitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse

(2013) Martin Lagging et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement

(2013) D. Husereau et al.   BMJ-British Medical Journal

Public health issues of hepatitis C virus infection

(2012) George Papatheodoridis et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections

(2011) Graham R. Foster et al.   GASTROENTEROLOGY

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

(2011) Markus Cornberg et al.   LIVER INTERNATIONAL

Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System

(2011) Klazien Matter-Walstra et al.   VALUE IN HEALTH

Does Medicare Have an Implicit Cost-Effectiveness Threshold?

(2010) James D. Chambers et al.   MEDICAL DECISION MAKING

Transportability of Comparative Effectiveness and Cost-Effectiveness between Countries

(2010) Andrew Briggs   VALUE IN HEALTH

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation

(2009) Konstantin J. Dedes et al.   EUROPEAN JOURNAL OF CANCER

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin

(2009) Michelle Martinot-Peignoux et al.   HEPATOLOGY

Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice

(2009) Marina Grishchenko et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Utilities of the EQ-5D

(2009) Saskia Knies et al.   PHARMACOECONOMICS

Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management

(2008) B. J. Thomson et al.   JOURNAL OF VIRAL HEPATITIS

The NICE Cost-Effectiveness Threshold

(2008) Christopher McCabe et al.   PHARMACOECONOMICS